Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
2021-02-12 4:39 pm Purchase | 13G | AEGLEA BIOTHERAPEUTICS, INC. C AGLE | ORBIMED ADVISORS LLC | 5,015,524 10.25% | 2,150,000 (+75.03%) | View |
2021-02-11 07:31 am Purchase | 13G | AEGLEA BIOTHERAPEUTICS, INC. C AGLE | ADAGE CAPITAL PARTNERS GP L.L.C. | 2,992,000 6.24% | 1,523,409 (+103.73%) | View |
2021-02-10 11:37 am Purchase | 13G | AEGLEA BIOTHERAPEUTICS, INC. C AGLE | PICTET ASSET MANAGEMENT SA | 2,519,334 5.25% | 2,519,334 (New Position) | View |
2021-02-10 06:35 am Purchase | 13G | AEGLEA BIOTHERAPEUTICS, INC. C AGLE | LV Management Group LLC | 103,533 0.2% | 103,533 (New Position) | View |
2021-02-02 2:56 pm Purchase | 13G | AEGLEA BIOTHERAPEUTICS, INC. C AGLE | BlackRock Inc. BLK | 3,239,975 6.8% | 1,327,666 (+69.43%) | View |
2020-10-26 4:36 pm Purchase | 13G | AEGLEA BIOTHERAPEUTICS, INC. C AGLE | Point72 Asset Management L.P. | 2,887,976 6.2% | 2,887,976 (New Position) | View |
2020-06-09 11:45 am Purchase | 13G | AEGLEA BIOTHERAPEUTICS, INC. C AGLE | BCLS II Equity Opportunities LP | 2,700,000 6.1% | 2,700,000 (New Position) | View |
2020-05-08 10:58 am Sale | 13G | AEGLEA BIOTHERAPEUTICS, INC. C AGLE | BlackRock Inc. BLK | 1,912,309 4.3% | -9,906 (-0.52%) | View |
2020-02-14 4:14 pm Unchanged | 13G | AEGLEA BIOTHERAPEUTICS, INC. C AGLE | BAKER BROS. ADVISORS LP | 1,713,604 5.9% | 0 (Unchanged) | View |
2020-02-14 12:00 pm Purchase | 13G | AEGLEA BIOTHERAPEUTICS, INC. C AGLE | ORBIMED ADVISORS LLC | 2,865,524 9.89% | 700,000 (+32.32%) | View |
2020-02-13 4:27 pm Purchase | 13G | AEGLEA BIOTHERAPEUTICS, INC. C AGLE | Nantahala Capital Management LLC | 2,852,260 9.8% | 325,000 (+12.86%) | View |
2020-02-13 4:17 pm Purchase | 13G | AEGLEA BIOTHERAPEUTICS, INC. C AGLE | Lilly Ventures Fund I LLC | 2,649,209 9.1% | 16,400 (+0.62%) | View |
2020-02-12 4:12 pm Purchase | 13G | AEGLEA BIOTHERAPEUTICS, INC. C AGLE | ADAGE CAPITAL PARTNERS GP L.L.C. | 1,468,591 5.07% | 10,000 (+0.69%) | View |
2020-02-06 2:01 pm Sale | 13G | AEGLEA BIOTHERAPEUTICS, INC. C AGLE | PRUDENTIAL FINANCIAL INC PRU | 33,765 0.1% | -1,319,605 (-97.51%) | View |
2020-02-05 11:25 am Purchase | 13G | AEGLEA BIOTHERAPEUTICS, INC. C AGLE | BlackRock Inc. BLK | 1,922,215 6.6% | 618,153 (+47.40%) | View |
2020-02-03 2:43 pm Sale | 13G | AEGLEA BIOTHERAPEUTICS, INC. C AGLE | JENNISON ASSOCIATES LLC | 0 0% | -1,351,790 (Position Closed) | View |
2020-01-30 4:12 pm Sale | 13G | AEGLEA BIOTHERAPEUTICS, INC. C AGLE | Novartis Bioventures Ltd | 617,769 2.13% | -620,000 (-50.09%) | View |